|
Volumn 96, Issue 3, 2001, Pages 858-863
|
Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: Implications for vaccination strategy
a a a a a a,b |
Author keywords
[No Author keywords available]
|
Indexed keywords
HEPATITIS A ANTIBODY;
HEPATITIS A VACCINE;
HEPATITIS B ANTIBODY;
HEPATITIS B CORE ANTIBODY;
HEPATITIS B SURFACE ANTIBODY;
HEPATITIS B VACCINE;
IMMUNOGLOBULIN G;
ACUTE HEPATITIS;
ADULT;
AGE;
ANTIBODY DETECTION;
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DEMOGRAPHY;
DISEASE ASSOCIATION;
DISEASE SEVERITY;
DRUG COST;
DRUG USE;
ETHNOLOGY;
EXPOSURE;
HEALTH CARE COST;
HEPATITIS A;
HEPATITIS A VIRUS;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HUMAN;
IMMUNITY;
INFECTION RISK;
MAJOR CLINICAL STUDY;
POLYMERASE CHAIN REACTION;
PREVALENCE;
PRIORITY JOURNAL;
QUESTIONNAIRE;
RISK FACTOR;
VACCINATION;
ADULT;
AFRICAN CONTINENTAL ANCESTRY GROUP;
AGING;
COST-BENEFIT ANALYSIS;
FEMALE;
HEPATITIS B VIRUS;
HEPATITIS C, CHRONIC;
HEPATOVIRUS;
HUMANS;
IMMUNITY;
IMMUNOLOGIC TESTS;
MALE;
MIDDLE AGED;
POLYMERASE CHAIN REACTION;
RISK FACTORS;
VACCINATION;
|
EID: 0035075772
PISSN: 00029270
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9270(00)02426-6 Document Type: Article |
Times cited : (48)
|
References (31)
|